Streetbeat News

Price Targets

GOSS

HC Wainwright & Co. has reaffirmed its Buy rating on Gossamer Bio (NASDAQ:GOSS) and increased its price target from $5.00 to $10.00. Gossamer Bio's shares have risen 7.06% in the last 24 hours to $0.91. The new price target suggests a potential upside of 998.9%. Gossamer Bio is a clinical-stage biopharmaceutical company with products in development for various diseases, including PAH, inflammatory bowel disease, oncology indications, and eosinophilic asthma.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 5:00 pm

RXST

RXSight shares surged following the company's preliminary revenue guidance for Q4, FY23, and FY24, which exceeded expectations. Additionally, Needham reaffirmed a Buy rating on RXSight and increased the price target from $35 to $41.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 4:58 pm

DE

Morgan Stanley analyst Angel Castillo has initiated coverage on Deere & Company (NYSE:DE) with an Overweight rating and set a price target of $430.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 4:58 pm

DCI

Morgan Stanley analyst Angel Castillo has initiated coverage on Donaldson (NYSE:DCI) with an Underweight rating and set a price target of $59.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 4:56 pm

KMT

Morgan Stanley analyst Angel Castillo has initiated coverage on Kennametal (NYSE:KMT) with an Equal-Weight rating and set a price target of $24 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 4:54 pm

LECO

Morgan Stanley analyst Angel Castillo has initiated coverage on Lincoln Electric Holdings (NASDAQ:LECO) with an Underweight rating and set a price target of $178.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 4:52 pm

DELL

Dell Technologies Inc (NYSE:DELL) shares rose in premarket trading on Jan. 8 due to a positive outlook from JPMorgan. Analyst Samik Chatterjee upgraded Dell from Neutral to Overweight and increased the price target from $77 to $90, citing the potential benefits from the AI-driven compute investment cycle. Chatterjee expects Dell to benefit from higher-end server sales, leading to increased average selling prices and operating margins. The upgrade reflects higher revenue and earnings forecasts for Dell in FY26, with the potential for double-digit earnings growth as the company moves past current macro pressures.

Portfolio Pulse from Priya Nigam

January 08, 2024 | 4:52 pm

TKR

Morgan Stanley analyst Angel Castillo has initiated coverage on Timken (NYSE:TKR) with an Equal-Weight rating and set a price target of $74 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 4:50 pm

ARMK

Truist Securities analyst Jasper Bibb has initiated coverage on Aramark (NYSE:ARMK) with a Buy rating and set a price target of $33. This new coverage could influence investor sentiment and potentially impact the stock's performance in the short term.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 4:42 pm

BCRX

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares rose after announcing preliminary unaudited Orladeyo net revenue of $89.9 million for Q4 and $325 million for full year 2023. The company expects 2024 global net revenue for Orladeyo to be between $380 million and $400 million. CEO Jon Stonehouse commented on the growth trajectory and the company's path to profitability. Needham analyst Serge Belanger reiterated a Buy rating and a $12 price target for BCRX, noting the potential for profitability by 2025 without additional capital.

Portfolio Pulse from Erica Kollmann

January 08, 2024 | 4:41 pm